Protagonist Therapeutics (PTGX) Current Deferred Revenue (2017 - 2026)

Protagonist Therapeutics has disclosed Current Deferred Revenue across 10 years of filings, most recently posting $6.3 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $6.3 million, down 62.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.3 million (down 62.82% YoY), and the FY2025 annual result was $9.5 million, down 49.45% from the prior year.
• Current Deferred Revenue came in at $6.3 million for Q1 2026 at Protagonist Therapeutics, down from $9.5 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $20.1 million in Q2 2024 to a low of $3000.0 in Q3 2023.
• The 5-year median for Current Deferred Revenue is $7.9 million (2025), against an average of $8.7 million.
• Across the five-year window, Current Deferred Revenue plunged 98.57% in 2022 and surged 656433.33% in 2024, its largest moves.
• Protagonist Therapeutics' Current Deferred Revenue stood at $69000.0 in 2022, then sank by 95.65% to $3000.0 in 2023, then soared by 629600.0% to $18.9 million in 2024, then tumbled by 49.45% to $9.5 million in 2025, then tumbled by 34.22% to $6.3 million in 2026.
• The last three Current Deferred Revenue figures came in at $6.3 million (Q1 2026), $9.5 million (Q4 2025), and $14.2 million (Q3 2025), per Business Quant data.